CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 6.83M shares outstanding
USCalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies.
The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
A. Rachel Leheny, Ph.D.
Chief Executive Officer and Class II Director
Dr. Glicklich
Board of Directors
Eric W. Roberts
Chief Business Officer & Vice Chairman of the Board
Kenneth A. Stauderman, Ph.D.
Chief Scientific Officer
Employees
16
Country
US
Sector
Healthcare
Website
calcimedica.com
Loading congressional disclosures…
based on 6.83M shares outstanding
US30d Avg
68.06K
60d Avg
84.39K
90d Avg
75.90K
